In a recent randomized controlled study, 24 patients with AF were randomly assigned to receive a single subcutaneous injection of 150 mg of canakinumab (a fully human monoclonal antibody targeting the IL-1β) or matching placebo after electrical cardioversion. This evidence concerns the gene IL1B and atrial fibrillation.